This Article  • Full text  • PDF  • eFigure and eTables  • JAMA Report Video  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Surgery  • Surgical Interventions  • Hepatobiliary Surgery  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael Bodmer, MD, MSc; Yolanda B. Brauchli, PhD, MSc; Stephan Krähenbühl, MD, PhD; Susan S. Jick, DSc; Christoph R. Meier, PhD, MSc

JAMA. 2009;302(18):2001-2007.

Context  Gallstone disease is a leading cause of morbidity in western countries and carries a high economic burden. Statins decrease hepatic cholesterol biosynthesis and may therefore lower the risk of cholesterol gallstones by reducing the cholesterol concentration in the bile. Data on this association in humans are scarce.

Objective  To study the association between the use of statins, fibrates, or other lipid-lowering agents and the risk of incident gallstone disease followed by cholecystectomy.

Design, Setting, and Participants  Case-control analysis using the UK-based General Practice Research Database. Incident patients between 1994 and 2008 and 4 controls per each patient were identified and matched on age, sex, general practice, calendar time, and years of history in the database. The study population was 76% women and the mean (SD) age was 53.4 (15.0) years at the index date. Conditional logistic regression was used to estimate the odds ratio (OR) of developing gallstones followed by cholecystectomy in relation to exposure to lipid-lowering agents, stratified by exposure timing and duration. The ORs and 95% confidence intervals (CIs) were adjusted for smoking, body mass index, ischemic heart disease, stroke, and estrogen use.

Main Outcome Measure  The adjusted OR (AOR) for developing gallstone disease followed by cholecystectomy in relation to exposure to lipid-lowering agents.

Results  A total of 27 035 patients with cholecystectomy and 106 531 matched controls were identified, including 2396 patients and 8868 controls who had statin use. Compared with nonuse, current statin use (last prescription recorded within 90 days before the first-time diagnosis of the disease) was 1.0% for patients and 0.8% for controls (AOR, 1.10; 95% CI, 0.95-1.27) for 1 to 4 prescriptions; 2.6% vs 2.4% (AOR, 0.85; 95% CI, 0.77-0.93) for 5 to 19 prescriptions, and 3.2% vs 3.7% (AOR, 0.64; 95% CI, 0.59-0.70) for 20 or more prescriptions. The AORs for current use of statins defined as 20 or more prescriptions were similar (around 0.6) across age, sex, and body mass index categories, and across the statin class.

Conclusion  Long-term use of statins was associated with a decreased risk of gallstones followed by cholecystectomy.

Author Affiliations: Division of Clinical Pharmacology and Toxicology (Drs Bodmer and Krähenbühl) and Hospital Pharmacy (Dr Meier), University Hospital, Basel, Switzerland; Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland (Drs Brauchli and Meier); and Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts (Drs Jick and Meier).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Statin Use and Gallstones
JWatch General 2009;2009:4-4.
FULL TEXT  

All you need to read in the other general journals
BMJ 2009;339:b4816-b4816.
FULL TEXT